ArticleThe Lancet. Microbe2022
Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations.
Article in The Lancet. Microbe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19.Microbiology spectrum · 2025Article
- Article
- Preamplification-free viral RNA diagnostics with single-nucleotide resolution using MARVE, an origami paper-based colorimetric nucleic acid test.Nature protocols · 2024Review
- Recombinant SARS-CoV-2 Delta/Omicron BA.5 emerging in an immunocompromised long-term infected COVID-19 patient.Scientific reports · 2024Article
- Using big sequencing data to identify chronic SARS-Coronavirus-2 infections.Nature communications · 2024Article
- Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy.Frontiers in oncology · 2024Article
- Article
- Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response.iScience · 2023Article
- COVID-19 in immunocompromised children: comparison of SARS-CoV-2 viral load dynamics between the first and third waves.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Within-Host Evolution of SARS-CoV-2 in a B-Cell Depleted Patient With Successful Treatment.Journal of Korean medical science · 2023Article
- Immunosuppressants exert differential effects on pan-coronavirus infection and distinct combinatory antiviral activity with molnupiravir and nirmatrelvir.United European gastroenterology journal · 2023Article
- Article
- Antigenic escape is accelerated by the presence of immunocompromised hosts.Proceedings. Biological sciences · 2022Article
- Early Outpatient Treatment With Remdesivir in Patients at High Risk for Severe COVID-19: A Prospective Cohort Study.Open forum infectious diseases · 2022Article
- N-Acetylcysteine and Other Sulfur-Donors as a Preventative and Adjunct Therapy for COVID-19.Advances in pharmacological and pharmaceutical sciences · 2022Review
- Rapid evolution of SARS-CoV-2 in domestic cats.Virus evolution · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.